Statin is a Reasonable Treatment Option for Patients with Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials

 

 Buy Article Permissions and Reprints

Abstract

Objectives:

To date no consensus has been reached on whether to administer statin to patients with Polycystic Ovary Syndrome (PCOS) routinely. Therefore, we conduct a meta-analysis to synthesize the literatures regarding therapeutic effects of statins on PCOS.

Methods:

A comprehensive literature search was performed using terms such as polycystic ovary syndrome, ovary polycystic disease, PCOS, hyperandrogaenemia; simvastatin, atorvastatin, lipidemic-modulating drugs, lipid lowering drugs, and testosterone; randomized controlled trials in the following bibliographic databases: Medline, Embase, Cochrane Controlled Trials Register. Identified reference lists were checked manually.

Results:

In total, 4 RCTs were included. 3 of 4 studies were double-blinded while none reported whether of the data was analyzed using intention-to-treat analysis. Serum total testosterone and lipid profiles were included as investigation outcomes. Differences in reducing serum total testosterone were observed when comparing statin with placebo (Std MD= − 3.03, 95%CI − 5.85 ~ − 0.22, P=0.03) or statin + metformin with metformin (Std MD=− 1.07, 95%CI: − 2.06~ − 0.07, P=0.04). Heterogeneities were detected in both comparisons (I²=96% and 88% respectively). Meanwhile, statin was more effective than placebo in reducing LDL (WMD=− 0.87, 95%CI  − 1.18~ − 0.55, P<0.0001), TC (WMD=− 1.23 95%CI  − 1.35~ − 1.11, P<0.00001), TG (WMD= − 0.50, 95%CI  − 0.73~ − 0.27, P<0.00001); and statin + metformin was more effective than metformin in lowering LDL (WMD= − 0.84, 95%CI:  − 1.33 ~ − 0.354, P=0.0009), TC (WMD= − 1.28, 95%CI: − 1.47 ~ − 1.10, P<0.00001), and TG (WMD= − 0.27, 95%CI:  − 0.36~ − 0.19, P<0.00001). Heterogeneities were detected during the meta-analysis.

Conclusions:

Statins can reduce the concentration of total testosterone, TC, TG and LDL. However, it cannot be concluded that statins have long-term benefit. A large-scale, randomized controlled study is needed to ascertain this uncertainty.

• References

• 1 March WA, Moore VM, Willson KJ et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction 2010; 25: 544-551
  CrossrefPubMedGoogle Scholar
• 2 Mehrabian F, Khani B, Kelishadi R et al. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynologia Polska 2011; 62: 238-242
  PubMedGoogle Scholar
• 3 Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Reviews in Cardiovascular Medicine 2009; 10: 83-90
  PubMedGoogle Scholar
• 4 Giallauria F, Orio F, Palomba S et al. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) 2008; 9: 987-992
  CrossrefPubMedGoogle Scholar
• 5 Lo JC, Feigenbaum SL, Yang J et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357-1363
  CrossrefPubMedGoogle Scholar
• 6 Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA et al. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18: 280-285
  CrossrefPubMedGoogle Scholar
• 7 Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111: 607-613
  CrossrefPubMedGoogle Scholar
• 8 Berneis K, Rizzo M, Hersberger M. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrom. Int J Clin Pract 2009; 63: 56-62
  CrossrefPubMedGoogle Scholar
• 9 Dahlgren E, Janson PO, Johansson S et al. Polycystic-Ovary-Syndrome and Risk for Myocardial-Infarction – Evaluated from a Risk Factor Model Based on a Prospective Population Study of Women. Acta Obstetricia Et Gynecologica Scandinavica 1992; 71: 599-604
  CrossrefPubMedGoogle Scholar
• 10 Ando H, Takamura T, Ota T et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294: 1043-1046
  PubMedGoogle Scholar
• 11 Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305
  CrossrefPubMedGoogle Scholar
• 12 Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). 1994. Atheroscler Suppl 2004; 5: 81-87
  PubMedGoogle Scholar
• 13 Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009
  CrossrefPubMedGoogle Scholar
• 14 Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307
  CrossrefPubMedGoogle Scholar
• 15 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94: 4938-4945
  CrossrefPubMedGoogle Scholar
• 16 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 456-461
  CrossrefPubMedGoogle Scholar
• 17 Duleba AJ, Banaszewska B, Spaczynski RZ et al. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertility and Sterility 2006; 85: 996-1001
  CrossrefPubMedGoogle Scholar
• 18 Kazerooni T, Azam S, Sedigheh D et al. Effects of metforimin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertility and Sterility 2010; 94: 2208-2213
  CrossrefPubMedGoogle Scholar
• 19 Raja-Khan N, Kunselman AR, Hogeman CS et al. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility 2011; 95: 1849-1852
  CrossrefPubMedGoogle Scholar
• 20 Sathyapalan T, Kilpatrick ES, Coady AM et al. The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. J Clin Endocrinol Metab 2009; 94: 103-108
  CrossrefPubMedGoogle Scholar
• 21 Sathyapalan T, Kilpatrick ES, Coady AM et al. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2010; 72: 566-568
  CrossrefPubMedGoogle Scholar
• 22 Cemil K, Sevim D, Biilent B. Compatative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertility and Sterility 2009; 92: 635-642
  CrossrefPubMedGoogle Scholar
• 23 Collier E, Carpentier JL, Beitz L et al. Specific glycosylation site mutations of the insulin receptor alpha subunit impair intracellular transport. Biochemistry 1993; 32: 7818-7823
  CrossrefPubMedGoogle Scholar
• 24 Hwang JB, Frost SC. Effect of alternative glycosylation on insulin receptor processing. J Biol Chem 1999; 274: 22813-22820
  CrossrefPubMedGoogle Scholar
• 25 Lee WC, Choi CH, Cha SH et al. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res 2005; 30: 263-270
  CrossrefPubMedGoogle Scholar
• 26 Kelly CC, Lyall H, Petrie JR et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455
  CrossrefPubMedGoogle Scholar
• 27 Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction 2006; 21: 1426-1431
  CrossrefPubMedGoogle Scholar
• 28 Ehrmann DA, Barnes RB, Rosenfield RL et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-146
  CrossrefPubMedGoogle Scholar
• 29 Baracat EC, Maciel GAR, Junior JMS et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility 2004; 81: 355-360
  CrossrefPubMedGoogle Scholar
• 30 Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010; CD003053
  PubMedGoogle Scholar
• 31 Diamanti-Kandarakis E, Alexandraki K, Protogerou A et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152: 749-756
  CrossrefPubMedGoogle Scholar
• 32 Moghetti P, Castello R, Negri C et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146
  CrossrefPubMedGoogle Scholar
• 33 Morin-Papunen LC, Koivunen RM, Ruokonen A et al. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility 1998; 69: 691-696
  CrossrefPubMedGoogle Scholar
• 34 Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2453-2461
  CrossrefPubMedGoogle Scholar
• 35 Carmina E, Rosato F, Janni A et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2-6
  CrossrefPubMedGoogle Scholar